Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1990-7-13
|
pubmed:abstractText |
On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix. Cisplatin was administered at a dosage of 100 mg/m2 iv bolus and 5-fluorouracil was continuously infused iv at a dosage of 1000 mg/m2/day for 4 days. In an effort to determine whether the toxicities of 5-fluorouracil could be ameliorated by coadministration of allopurinol, patients were randomized to receive allopurinol, 900 mg orally, an odd or even courses of therapy beginning 5 days before 5-fluorouracil administration and continuing until conclusion of the infusion. Fifty-two eligible patients received 177 evaluable courses of treatment. The overall response rate was 28% (8 complete responses and 6 partial responses). Toxicity was confined to nausea and vomiting (81% of courses), anemia (47%), leukopenia (37%), oral mucositis (15%), diarrhea (6%), and thrombocytopenia (4%). Allopurinol produced no improvement in treatment-related toxicities. Allopurinol did not permit substantial increases in 5-fluorouracil dosage.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0090-8258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
354-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2351319-Adult,
pubmed-meshheading:2351319-Aged,
pubmed-meshheading:2351319-Allopurinol,
pubmed-meshheading:2351319-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2351319-Blood Cell Count,
pubmed-meshheading:2351319-Carcinoma,
pubmed-meshheading:2351319-Cisplatin,
pubmed-meshheading:2351319-Drug Evaluation,
pubmed-meshheading:2351319-Female,
pubmed-meshheading:2351319-Fluorouracil,
pubmed-meshheading:2351319-Gastrointestinal Diseases,
pubmed-meshheading:2351319-Humans,
pubmed-meshheading:2351319-Middle Aged,
pubmed-meshheading:2351319-Neoplasm Recurrence, Local,
pubmed-meshheading:2351319-Survival,
pubmed-meshheading:2351319-Uterine Cervical Neoplasms
|
pubmed:year |
1990
|
pubmed:articleTitle |
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial.
|
pubmed:affiliation |
University of Texas Health Science Center, San Antonio.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|